2,842
edits
Psychedelics: Difference between revisions
m
no edit summary
mNo edit summary |
mNo edit summary |
||
| Line 132: | Line 132: | ||
|Ibogaine | |Ibogaine | ||
| | | | ||
|0.87mg/kg<ref>'''Ibogaine for treating drug dependence. What is a safe dose?''' Drug Alcohol Depend. Schep LJ, Slaughter RJ, Galea S, Newcombe D. 2016 Sep 1;166:1-5. doi: 10.1016/j.drugalcdep.2016.07.005. Epub 2016 Jul 15. PMID: 27426011. Accessed on 17th Jul 2023 via https://pubmed.ncbi.nlm.nih.gov/27426011/</ref> | |||
| | | | ||
| | |1-3 hours | ||
| | |Up to 48 hours<ref>'''Tabernanthe iboga is a shrub of West Africa, whose roots are used for stimulatory, hallucinogenic, and sedative properties (Ujváry, 2014)'''. Addictive Substances and Neurological Disease, 2017. Accessed 17 Jul 2023 via: https://www.sciencedirect.com/topics/neuroscience/tabernanthe-iboga</ref> | ||
| >4 weeks | | >4 weeks | ||
|- | |- | ||
| Line 143: | Line 143: | ||
|400 mg | |400 mg | ||
|1000 mg | |1000 mg | ||
| | |<30 mins | ||
|8-15 hours | |8-15 hours | ||
| - | | - | ||
| Line 152: | Line 152: | ||
|75-140mg | |75-140mg | ||
| | | | ||
|20- | |20-30 min | ||
|2-4 hours | |2-4 hours | ||
|2 weeks | |2 weeks | ||
| Line 163: | Line 163: | ||
| | | | ||
| | | | ||
| | | - | ||
|- | |- | ||
|'''Dissociative''' | |'''Dissociative''' | ||
|[[Ketamine]] | |[[Ketamine]] (Intranasal) | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|<30 minutes | |||
|2 days | |2 days | ||
|- | |- | ||
| Line 181: | Line 181: | ||
| | | | ||
| | | | ||
| | | - | ||
|} | |} | ||
[[File:Psychedelic neuroplasticity period.png|alt=Psychedelic neuroplasticity period|thumb|'''Figure 4'''. Psychedelics differ in how long they induce a social reward learning period]] | [[File:Psychedelic neuroplasticity period.png|alt=Psychedelic neuroplasticity period|thumb|'''Figure 4'''. Psychedelics differ in how long they induce a social reward learning period]] | ||